Downregulation of AHNAK2 inhibits cell cycle of lung adenocarcinoma cells by interacting with RUVBL1
Thoracic Cancer · 2023
DOI: 10.1111/1759-7714.14989 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Xin Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Chaoyang Hospital, Beijing, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Lung adenocarcinoma (LUAD) is the leading cause of death among cancer diseases. The tumorigenic functions of AHNAK2 in LUAD have attracted more attention in recent years, while there are few studies which have reported its high molecular weight.
Methods
The mRNA‐seq data of AHNAK2 and corresponding clinical data from UCSC Xena and GEO was analyzed. LUAD cell lines were transfected with sh‐NC and sh‐AHNAK2, and cell proliferation, migration and invasion were then detected by in vitro experiments. We performed RNA sequencing and mass spectrometry analysis to explore the downstream mechanism and interacting proteins of AHNAK2. Finally, western blot, cell cycle analysis and CO‐IP were used to confirm our assumptions regarding previous experiments.
Results
Our study revealed that AHNAK2 expression was significantly higher in tumors than in normal lung tissues and higher AHNAK2 expression led to a poor prognosis, especially in patients with advanced tumors. AHNAK2 suppression via shRNA reduced the LUAD cell lines proliferation, migration and invasion and induced significant changes in DNA replication, NF‐kappa B signaling pathway and cell cycle. AHNAK2 knockdown also caused G1/S phase cell cycle arrest, which could be attributed to the interaction of AHNAK2 and RUVBL1. In addition, the results from gene set enrichment analysis (GSEA) and RNA sequencing suggested that AHNAK2 probably plays a part in the mitotic cell cycle.
Conclusion
AHNAK2 promotes proliferation, migration and invasion in LUAD and regulates the cell cycle via the interaction with RUVBL1. More studies of AHNAK2 are still needed to reveal its upstream mechanism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Chaoyang Hospital, Beijing, China.
- Thoracic Surgery, Beijing Chao-yang Hospital, Beijing, China.
- Beijing Chao-Yang Hospital Capital Medical University, Beijing, China.
- Department of Thoracic Surgery, Beijing Chao-Yang Hospital Affiliated Capital Medical University, Beijing, China.
Zitieren
APA
Li, X., Li, H., Shao, M. M., Miao, J., Fu, Y., & Hu, B. (2023). Downregulation of AHNAK2 inhibits cell cycle of lung adenocarcinoma cells by interacting with RUVBL1. Thoracic Cancer. https://doi.org/10.1111/1759-7714.14989
Vancouver
Li X, Li H, Shao MM, Miao J, Fu Y, Hu B. Downregulation of AHNAK2 inhibits cell cycle of lung adenocarcinoma cells by interacting with RUVBL1. Thoracic Cancer. 2023. doi:10.1111/1759-7714.14989
BibTeX
@article{Li2023,
author = {Li, Xin and Li, Hui and Shao, Ming-Ming and Miao, Jinbai and Fu, Yili and Hu, Bin},
title = {Downregulation of AHNAK2 inhibits cell cycle of lung adenocarcinoma cells by interacting with RUVBL1},
journal = {Thoracic Cancer},
year = {2023},
doi = {10.1111/1759-7714.14989}
}
EUVIMED